Recode, new life
Reforgene Medicine develops gene editing therapies for genetic diseases and diseases with major unmet need.
Curative answers, starting at the genome
Reforgene Medicine is one of China’s leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life.
The company has pipeline programs in genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world’s first cure of an alpha-thalassemia patient.
Learn more →
How gene editing becomes a cure
Rewriting a disease-causing gene at the genome level is the path to a one-time, curative gene editing medicine.
01 Pinpoint the target gene
The TIPBAIG™ platform combines genomics and AI to discover and validate targets, tracing disease to a specific gene.
02 Edit with precision
CRISPR/Cas systems, such as base editors, make precise changes at specified sites. Editing can be performed ex vivo or delivered in vivo using LNP or AAV.
03 One-time cure
Corrected cells restore normal function, enabling a one-time administration with long-term or even lifelong benefit.
Therapeutic Areas
Gene editing is turning genetic diseases and major prevalent diseases into curable conditions.
More than 7,000 genetic diseases,
most without effective treatment
Gene editing brings new hope for true cures. Reforgene focuses on genetic diseases of the blood and the eye.
Cardiovascular, metabolic and more,
gene editing moves toward prevalent diseases
Reforgene continues to explore gene editing medicines for prevalent diseases, spanning cardiovascular, metabolic, infectious and autoimmune diseases.
Three Platforms, One System
An end-to-end system for gene editing drug development, from tool discovery and target identification to safety assessment.
Digital drug development platform
Combining AI, informatics and genomics, TIPBAIG™ accelerates gene editing therapy development from tool engineering to safety assessment.
Gene editing technology platform
Integrating CRISPR/Cas systems, base editors and novel LNP delivery tools.
Product platform
Spanning ex vivo cell engineering and in vivo delivery.
Newsroom
Company updates and industry progress. Please refer to official announcements.
Reforgene named among China's Top 100 Innovative Pharmaceutical Companies 2026
Reforgene named a Future Healthcare Top 100 company for the fourth consecutive year
Guangzhou Industry and Information Technology Bureau delegation visits Reforgene
TIF and the Angel Mama Foundation visit Reforgene to advance global access for thalassemia gene medicine
Guangzhou Municipal Government delegation visits Reforgene
